RAPTURE Preworkout Recall: What DMAA Is and Why FDA Still Finds It

The lot behind the RAPTURE recall

On October 7, 2026, the FDA published a company announcement that Leader Formulas, LLC. of Tomball, Texas is voluntarily recalling one lot of RAPTURE Preworkout, a dietary supplement powder. FDA testing found DMAA in the product. The agency's position is that DMAA is not a dietary ingredient, that selling it in a supplement violates the law, and that it has been pursuing the substance since 2012.

The affected lot is 260327-4, sold in three flavors. The product ships in 450 g round plastic containers with red and black lettering and a rhinoceros print seal on top of the container.

The company says the product was distributed between January 29, 2025 and May 25, 2026 nationwide to retail and through its own website, leaderformulas.com.

Three dates surround the recall and they do not line up. The company's own notice, marked for immediate release on its site, is dated October 1, 2026. The FDA lists the company announcement date as October 6, 2026 and its own publish date as October 7, 2026.

What the two notices actually state

The stated reason for the announcement is narrow: "Product contains 1,3-Dimethylamylamine (DMAA)." The announcement says the issue was discovered in the product during testing by the FDA, and that the company has not received any reports of adverse events related to this recall. The recall is being conducted with the knowledge of the FDA.

Neither the FDA posting nor the company notice says whether DMAA was declared anywhere on the label, so this is a finding about what was in the tub rather than a finding about what the label said.

How FDA describes DMAA

FDA's own page on the ingredient calls DMAA "an amphetamine derivative" that has been marketed in sports performance and weight loss products, many of which are sold as dietary supplements. On its legal status the agency is explicit: "DMAA is not a dietary ingredient, and DMAA-containing products marketed as dietary supplements are illegal and their marketing violates the law."

FDA says it has no information demonstrating that consuming DMAA is safe, and that when DMAA is added to a product marketed as a dietary supplement the agency considers it an unsafe food additive. The same page describes the mechanism as narrowing blood vessels and arteries, which can raise blood pressure and may lead to cardiovascular problems including shortness of breath, arrhythmias, tightening in the chest and heart attack, as well as seizures and other neurological and psychological conditions. It adds that the risk grows when DMAA is combined with other stimulants such as caffeine.

The agency also disputes the marketing story around the ingredient. FDA says DMAA is often touted as a "natural" stimulant and is sometimes listed as geranium extract, but that it is not aware of any reliable science indicating that DMAA exists naturally in plants. DMAA was at one time approved as a drug for nasal decongestion. It is no longer approved for that use, and FDA says no medical use of DMAA is recognized today.

That assessment is the agency's standing position rather than a finding about this recall. The page carrying it is dated August 2018 in the body text and marked current as of February 22, 2023.

Eleven label names and two plant extracts

For anyone holding a different brand, the most useful part of this recall is FDA's list of label entries that can indicate DMAA: 1,3-DMAA, 1,3-dimethylamylamine, 1,3-dimethylpentylamine, 2-amino-4-methylhexane, 2-hexanamine, 4-methyl- (9CI), 4-methyl-2-hexanamine, 4-methyl-2-hexylamine, dimethylamylamine, geranamine, methylhexanamine and methylhexanenamine. FDA adds that products listing Pelargonium graveolens extract or geranium extract may also indicate the presence of DMAA.

A lot number covers one tub in one recall. Those synonyms apply to any supplement label in front of you.

Fourteen years of warning letters and seizures

FDA's enforcement record on DMAA runs back to 2012. The agency says it began issuing warning letters that year telling companies that marketing DMAA-containing products violates the law, and the same page lists 18 warning letters issued between 2012 and 2017.

When firms did not comply voluntarily, the agency used other tools. In 2013, FDA administratively detained two DMAA-containing products, OxyElite Pro and Jack3d, after USPLabs initially refused the agency's efforts to achieve voluntary compliance. FDA says USPLabs ultimately destroyed the detained products, estimated to have been worth more than $8 million at the retail level, and agreed to stop manufacturing with DMAA. Also in 2013, the agency seized DMAA-containing products from Hi-Tech Pharmaceuticals. A federal district court ruled in April 2017 that the products were adulterated and ordered them condemned and forfeited to the United States. The U.S. Court of Appeals for the Eleventh Circuit affirmed in 2019, finding that DMAA is not a dietary ingredient and is not generally recognized as safe. The Supreme Court denied a request to review the case in 2020, and FDA says the products were destroyed on November 12, 2020.

FDA's own summary of that history is that it "continues working to get DMAA products off the market when it identifies them." The RAPTURE finding is one more detection in that sequence.

Why the tub ships before FDA tests it

How supplements are regulated explains the order of events. FDA's dietary supplement page says supplements fall under a different set of rules than conventional foods and drug products, under the Dietary Supplement Health and Education Act of 1994. Manufacturers and distributors are prohibited from marketing adulterated or misbranded products, and firms "are responsible for evaluating the safety and labeling of their products before marketing." FDA's authority to act against an adulterated or misbranded supplement applies after it reaches the market.

That division of labor shows in the timeline. The lot shipped for roughly 16 months, FDA tested it, and the removal is voluntary and conducted with the agency's knowledge.

Checking a tub against lot 260327-4

Check the lot number against 260327-4, and check the flavor and UPC against the three rows above. If the lot number matches, stop using the product and return it to the place of purchase for a full refund.

Leader Formulas says it is notifying distributors and customers by mail and arranging for the return of all recalled products. Questions about the recall go to the company at [email protected] or 832-855-7562, Monday through Friday, 9 AM to 5 PM Central Time.

The company notice also directs consumers who have had problems they think may be related to contact a physician or healthcare provider. It says adverse reactions or quality problems can be reported to FDA's MedWatch program online, by regular mail or by fax, with a reporting form available by calling 1-800-332-1088.

Three details neither notice supplies

Whether DMAA was declared on the label. Neither notice says.

How DMAA got into the lot. Neither notice describes a cause or says whether the finding was contamination or an addition.

When FDA tested the product. The distribution window closes on May 25, 2026, more than four months before the notice went out, and no document explains the gap.

What the documents do establish is specific: one lot, three flavors, one ingredient FDA says cannot lawfully be in a dietary supplement, and a refund route at the point of purchase.